In patients with chronic kidney disease (CKD), strong evidence from large randomized controlled trials (RCTs) has consistently shown that SGLT-2 inhibitors can significantly reduce kidney disease progression and cardiac death by 28-39%.20–22 These reno-protective effects are particularly notable in patients, irrespective of coexisting type 2 diabetes (T2DM).9 Nevertheless, there remains a paucity of large-scale randomized controlled trials (RCTs) and comprehensive meta-analyses to conclusively validate the efficacy and safety profile of SGLT-2 inhibitors in KTRs. The gene discussed is SLC5A2; the disease is kidney disorder.